EAVI2020 EAVI2020 on Twitter EAVI2020 on Facebook EAVI2020 on LinkedIn

EAVI2020 begins new HIV vaccine trial at Oxford University

The new trial will evaluate the HIVconsvX vaccine – a mosaic vaccine targeting a broad range of HIV-1 variants, making it potentially applicable for HIV strains in any geographical region.

 

On 5 July, the EAVI2020 team at University of Oxford started vaccinations of a novel HIV vaccine candidate as part of a Phase I clinical trial in the UK.

The goal of the trial, known as HIV-CORE 0052, is to evaluate the safety, tolerability, and immunogenicity of the HIVconsvX vaccine. The novel mosaic vaccine works by targeting a broad range of HIV-1 variants, making it potentially applicable for HIV strains in any geographical region.

While most HIV vaccine candidates work by inducing antibodies generated by B-cells, HIVconsvX induces the immune system’s potent, pathogen obliterating T cells, targeting them to highly conserved and therefore vulnerable regions of HIV – an “Achilles heel” common to most HIV variants.

Professor Tomáš Hanke, Professor of Vaccine Immunology at the Jenner Institute, University of Oxford, and lead researcher on the trial, said: ‘An effective HIV vaccine has been elusive for 40 years. This trial is the first in a series of evaluations of this novel vaccine strategy in both HIV-negative individuals for prevention and in people living with HIV for cure.’

The consortium hopes to be able to report results of the HIV-CORE 0052 trial by April 2020.

ITV News Health Editor Emily Morgan has met the scientists behind the trial and those taking part, watch the full ITV news clip here.

Latest Posts

animated hands holding up red ribbon
EAVI2020 continues the…
December 1, 2021
info card on clinical trial EAVI2020 - 3SM
World AIDS DAY Part 1:…
December 1, 2021
info card on clinical trial HIV-CORE 0051
World AIDS DAY Part 4:…
December 1, 2021